Company Vincerx Pharma, Inc.

Equities

VINC

US92731L1061

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
0.7479 ^USD	-2.18%		-9.89%	-36.62%

Apr. 26	Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday	MT
Apr. 26	Vincerx Pharma Prices Public Offering of Shares, Warrants	MT

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.

Number of employees: 42

Managers	Title	Age	Since
Soo In Hwang FOU	Founder	64	18-12-18
Raquel Izumi FOU	Founder	54	18-12-18
Tom Thomas FOU	Founder	64	18-12-18
Ahmed Hamdy CEO	Chief Executive Officer	59	18-12-18
Alexander Seelenberger Farba DFI	Director of Finance/CFO	45	20-11-30
Amy Johnson CTO	Chief Tech/Sci/R&D Officer	-	21-02-28
Hans-Georg Lerchen CTO	Chief Tech/Sci/R&D Officer	-	21-03-01
Tasheda Navarro CTO	Chief Tech/Sci/R&D Officer	-	-
Melissa Merrick HRO	Human Resources Officer	-	21-02-28
Bill Donaldson LAW	General Counsel	-	-

Members of the board	Title	Age	Since
Ahmed Hamdy CEO	Chief Executive Officer	59	18-12-18
Laura Bushnell BRD	Director/Board Member	56	20-12-22
Brian Druker BRD	Director/Board Member	68	20-12-22
Ruth Stevens BRD	Director/Board Member	64	20-12-31
John Lee BRD	Director/Board Member	56	20-12-22
Francisco Salva BRD	Director/Board Member	53	20-12-22
Raquel Izumi FOU	Founder	54	18-12-18

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	27,407,510	22,010,613 ( 80.31 %)	0	80.31 %

Name	Equities	%	Valuation
Lifesci Investments LLC 9.377 %	2,570,000	9.377 %	2 M $
Prosight Management LP 9.111 %	2,497,218	9.111 %	2 M $
Ahmed Hamdy 6.255 %	1,714,259	6.255 %	2 M $
Raquel Izumi 6.219 %	1,704,413	6.219 %	2 M $
Sage Rhino Capital LLC 6.215 %	1,703,413	6.215 %	2 M $
John Byrd 5.904 %	1,618,199	5.904 %	1 M $
Octagon Capital Advisors LP 3.649 %	1,000,000	3.649 %	897 000 $
Point72 Asset Management LP 3.484 %	954,827	3.484 %	856 480 $
Rock Springs Capital Management LP 3.254 %	891,719	3.254 %	799 872 $
BofA Securities, Inc. 2.559 %	701,423	2.559 %	629 176 $

Vincerx Pharma, Inc.

260 Sheridan Avenue Suite 400

94306, Palo Alto

http://www.vincerapharma.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7479 USD

Average target price

9 USD

Spread / Average Target

+1,103.37%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VINCERX PHARMA, INC.	-36.62%	22.09M
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	113B
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B
ARGENX SE	+1.05%	22.27B
BIONTECH SE	-12.64%	22.22B
GENMAB A/S	-5.24%	19.43B
WUXI APPTEC CO., LTD.	-37.85%	17.87B
BEIGENE, LTD.	-8.58%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.77%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.52B

Bio Therapeutic Drugs